Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10700982 | 0.73 | CRBN (0.50) | CRBNMAP3K14DDB1BRD4CREBBP | |
| SCHEMBL19972725 | 0.73 | CRBN (0.50) | CRBNMAP3K14DDB1BRD4CREBBP | |
| SCHEMBL19972724 | 0.73 | CRBN (0.50) | CRBNMAP3K14DDB1BRD4CREBBP | |
| SCHEMBL8736478 | 0.71 | MAP3K14 (0.44) | CRBNMAP3K14DDB1CYP19A1GAA | |
| SCHEMBL26620901 | 0.70 | CRBN (0.46) | CRBNMAP3K14BRD4CREBBPCYP19A1 | |
| SCHEMBL26620905 | 0.70 | CRBN (0.46) | CRBNMAP3K14BRD4CREBBPCYP19A1 | |
| SCHEMBL26620904 | 0.70 | CRBN (0.46) | CRBNMAP3K14BRD4CREBBPCYP19A1 | |
| SCHEMBL26620903 | 0.70 | CRBN (0.46) | CRBNMAP3K14BRD4CREBBPCYP19A1 | |
| SCHEMBL162371 | 0.67 | — | — | |
| SCHEMBL14387952 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CRBN 50/4885MAP3K14 555/4885DDB1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.